Clinical evaluation of the effect of ferric citrate hydrate in hemodialysis patients with renal anemia and hyperphosphatemia

Clinical evaluation of the effect of ferric citrate hydrate in hemodialysis patients with renal anemia and hyperphosphatemia - The effect of ferric citrate hydrate in hemodialysis patients with renal anemia and hyperphosphatemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025478

Enrollment

Registered

2016-12-31

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage kidney disease with renal and iron deficiency anemia and hyperphosphatemia

Interventions

oral administration of ferric citrate hydrate for 52weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Iron deficiency anemia TSAT<20%,Ferritin<100ng/ml

Exclusion criteria

Exclusion criteria: History of hypersensitivity to ferric citrate Intake of other Iron-contained drugs digestive hemorrhage or IBD patient pregnancy or planned pregnancy malignancy physician's decision

Design outcomes

Primary

Measure	Time frame
After 52 weeks 1. The rate of the accomplishment of the target of IP(3.5~6.0mg/dl) 2. The rate of the accomplishment of the target of Hb(10~12g/dl) and the average 3. Dose of ferric citrate hydrate	—

Secondary

Measure	Time frame
1. Fe Ferritin TSAT 2. cCa 3. Alb 4. hsCRP 5. BNP 6. Hb cyclimg 7. side effect 8. Dose of ESA	—

Countries

Japan

Contacts

Public ContactHironobu Inoue

Saiseikai Kumamoto Hospital kidney and urology center

hironobu-inoue@saiseikaikumamoto.jp096-351-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026